GlassScriptPhysician profile
Andrew Kelly
NPI 1437492949
$3,622.20
in general payments reported to CMS, 2019-2025
25 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $72.24 · 2021: $209 · 2022: $251 · 2023: $838 · 2024: $791 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.28 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.72 | 2021-2025 | |
| Pfizer INC. | $520.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $400.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $380.56 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $266.69 | 2019-2025 | Spravato |
| Novo Nordisk INC | $214.02 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $190.30 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $186.31 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $127.33 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.28 | 2024-2025 | Jardiance, Ofev |
| Stryker Corporation | $102.00 | 2019 | |
| Exact Sciences Corporation | $95.45 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $95.37 | 2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $58.32 | 2023-2024 | |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.82 | 2022-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Dynavax Technologies Corporation | $40.67 | 2023-2024 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $40.38 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.54 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $32.46 | 2024-2025 | Voquezna |
| Lundbeck LLC | $30.54 | 2025 | Rexulti |
| Cranial Technologies, INC | $19.65 | 2025 | Doc Band |
| Otsuka America Pharmaceutical, INC. | $19.11 | 2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $16.47 | 2021 | |
| Allergan, INC. | $13.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.